-The Hindu Over 95 per cent of patients coming to super-speciality hospitals are at the wrong place and have incurred hardships when they could have been treated at their neighbourhood primary care centre. A number of announcements have been made by the Central and State governments on their intent to offer Universal Health Care (UHC). These welcome developments are timely as India is now rapidly becoming one of the few countries that...
More »SEARCH RESULT
Total Matching Records found : 520
Made for Big Pharma -Paranjoy Guha Thakurta
-Deccan Chronicle Prime Minister Narendra Modi may be patting himself on the back because President Barack Obama has agreed to India's position on food stockholding norms in World Trade Organisation (WTO). However, New Delhi seems to be bending over backwards to accommodate the American government and giant multinational corporations (MNCs) in the pharmaceutical industry, which will work to the detriment of our country's interests. In less than six months, the Modi government...
More »A reality check on intellectual property concerns -Moushami Joshi and Srividhya Ragavan
-The Hindu The Working Group on Intellectual Property can serve as a platform where real time solutions to meet India's need for low-cost medicines can be addressed After what seemed like a historic trip for Prime Minister Narendra Modi, which held out the promise of reshaping India-U.S. relations positively, the initiation of the Out-of-Cycle Review (OCR) by the United States Trade Representative (USTR) has brought a sobering reality check as to what...
More »NRIs filed 78% of the patent pleas in India -Sushmi Dey
-The Times of India NEW DELHI: India registered the third highest rate for patent filings by non-residents at 78% of the total applications, ahead of China at 18%, Japan at 16% and the US at 50%, the latest data from the Indian patent office showed. Canada and Brazil topped the list with 86.6% and 84%, respectively. Officials opine this is an indicator of lack of awareness amongst the domestic industry as well...
More »New hepatitis drug to cost more in middle income nations; activists cry foul -Jyotsna Singh
-Down to Earth Pharma company's strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)'s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment. BMS had announced that it would create a tiered pricing strategy for...
More »
